Imaging Technology

JUNE 15, 2023

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use. Fruhwirth, G. Kneilling, M., De Vries, I. Weigelin, B.,

Radiopharmaceuticals 84

Radiopharmaceuticals Pharmaceutical Nuclear Medicine PET Scan 84

AuntMinnie

FEBRUARY 12, 2024

In patients treated at a memory clinic at Huashan Hospital in Shanghai, amyloid PET scans detected brain pathology associated with the disease and led to changes in treatment plans in 36.5% The clinical utility of amyloid PET scans has been systematically studied in many other countries. in 2012. “The

PET Scan 100

PET Scan Disease Diagnose Radiopharmaceuticals 100

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 Gauden , D.Phil., 18F-rhPSMA-7.3

Diagnostic 89

Diagnostic Radiopharmaceuticals Imaging Radiation 89

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,

Diagnostic 72

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 72

AuntMinnie

JANUARY 19, 2024

This can only be accomplished with a combination of innovative diagnostic, treatment, and monitoring technology that can enable timely interventions and personalized treatment plans. More accurate diagnostic and monitoring tools can also help manage the high cost of new therapies by preventing the misuse of expensive treatments.

Disease 52

Disease Medicare Imaging PET Scan 52

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52